Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned an average recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $58.4118.

A number of brokerages have issued reports on RARE. Guggenheim cut their target price on Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Cantor Fitzgerald raised their price target on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a research report on Thursday, May 21st. Truist Financial raised Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. Royal Bank Of Canada boosted their price objective on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Finally, Barclays decreased their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the sale, the executive vice president owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This trade represents a 1.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the transaction, the director owned 21,095 shares of the company’s stock, valued at $528,429.75. This trade represents a 8.66% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 19,319 shares of company stock valued at $476,837. 5.20% of the stock is currently owned by company insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after buying an additional 29,984 shares during the period. Creative Planning purchased a new position in Ultragenyx Pharmaceutical during the second quarter worth about $454,000. American Century Companies Inc. acquired a new stake in Ultragenyx Pharmaceutical in the second quarter valued at about $366,000. M&T Bank Corp boosted its holdings in Ultragenyx Pharmaceutical by 19.7% in the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock valued at $263,000 after purchasing an additional 1,192 shares in the last quarter. Finally, Amundi grew its holdings in Ultragenyx Pharmaceutical by 1,560.4% during the second quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock worth $3,913,000 after acquiring an additional 93,189 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 3.1%

Ultragenyx Pharmaceutical stock opened at $29.28 on Monday. The stock has a market cap of $2.88 billion, a P/E ratio of -4.79 and a beta of 0.31. The company has a 50-day moving average price of $27.28 and a 200 day moving average price of $24.46. Ultragenyx Pharmaceutical has a 12-month low of $18.29 and a 12-month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The business had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company’s revenue was down 2.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.57) earnings per share. As a group, analysts forecast that Ultragenyx Pharmaceutical will post -4.53 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.